Compare · MRNA vs PTHS
MRNA vs PTHS
Side-by-side comparison of Moderna Inc. (MRNA) and Pelthos Therapeutics Inc. (PTHS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and PTHS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $63.41B, about 608.9x PTHS ($104.1M).
- Over the past year, MRNA is up 541.9% and PTHS is up 28.0% - MRNA leads by 514.0 points.
- MRNA has been more active in the news (10 items in the past 4 weeks vs 9 for PTHS).
- MRNA has more recent analyst coverage (25 ratings vs 6 for PTHS).
- Company
- Moderna Inc.
- Pelthos Therapeutics Inc.
- Price
- -
- -
- Market cap
- $63.41B
- $104.1M
- 1M return
- +185.74%
- +0.92%
- 1Y return
- +541.94%
- +27.97%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 2018
- 2024
- News (4w)
- 10
- 9
- Recent ratings
- 25
- 6
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- Moderna upgraded by Wolfe Research
- Moderna upgraded by BofA Securities
- Moderna upgraded by William Blair
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- SEC Form SCHEDULE 13G filed by Moderna Inc.
- Chief Executive Officer Bancel Stephane exercised 751,715 shares at a strike of $19.15 and sold $28,715,011 worth of shares (499,246 units at $57.52) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 6,440,260 units (SEC Form 4) to satisfy withholding tax
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
- SEC Form 144 filed by Moderna Inc.
- Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
Latest PTHS
- SEC Form DEFA14A filed by Pelthos Therapeutics Inc.
- SEC Form DEF 14A filed by Pelthos Therapeutics Inc.
- SEC Form 10-Q filed by Pelthos Therapeutics Inc.
- Pelthos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits
- Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
- Amendment: SEC Form 10-Q/A filed by Pelthos Therapeutics Inc.
- Pelthos Therapeutics Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
- SEC Form PRE 14A filed by Pelthos Therapeutics Inc.
- Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
- Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders